Market Cap 583.42M
Revenue (ttm) 40,000.00
Net Income (ttm) -88.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -220,225.00%
Debt to Equity Ratio 0.12
Volume 2,470,500
Avg Vol 4,490,700
Day's Range N/A - N/A
Shares Out 194.47M
Stochastic %K 36%
Beta 0.27
Analysts Strong Sell
Price Target $14.59

Company Profile

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
lottomillions
lottomillions Aug. 19 at 12:17 PM
$ALT The XBI might do it today, ALT and Durso still asleep.
0 · Reply
Turribull
Turribull Aug. 19 at 12:13 PM
$ALT Reverse inverse oppo Cramer.
0 · Reply
TradeSun
TradeSun Aug. 19 at 12:06 PM
$ALT Good morning ☀️ RECLAIM’s positive AUD data were released on July 28. Jerry Durso bought 15,000 shares just 16 days later, likely too soon for newly sparked Big Pharma interest to have developed into advanced, material negotiations. His purchase therefore doesn’t contradict a potential partnership scenario. It suggests that, as of August 13, any possible discussions were probably still too preliminary or non-material to prevent him from buying. The timeline would make sense: -> Positive AUD data attract interest -> Initial contacts and NDAs follow -> Due diligence takes place over the coming months -> The FDA EOP2 meeting provides regulatory clarity -> Concrete offers could emerge thereafter This fits the thesis that RECLAIM may have activated one or more interested parties, just not that a deal was already close to signing when Durso bought.
1 · Reply
ItIsGoTime
ItIsGoTime Aug. 19 at 12:06 PM
$ALT institution held jumps to over 75%
0 · Reply
GreenEnergy7B
GreenEnergy7B Aug. 19 at 11:54 AM
$ALT Flying $MRNA
0 · Reply
ghettobird
ghettobird Aug. 19 at 11:40 AM
1 · Reply
ViperV22
ViperV22 Aug. 19 at 11:35 AM
0 · Reply
szrdz
szrdz Aug. 19 at 11:05 AM
$ALT me looking at moderna
2 · Reply
Jackstradamus
Jackstradamus Aug. 19 at 10:17 AM
$ALT https://www.cnbc.com/video/2026/08/18/lightning-round-avnet-is-a-really-good-stock-says-jim-cramer.html
1 · Reply
Babybock
Babybock Aug. 19 at 10:14 AM
$ALT very
0 · Reply
Latest News on ALT
Altimmune reports Q2 EPS (12c), consensus (12c)

2026-08-17T09:49:10.000Z - 2 days ago

Altimmune reports Q2 EPS (12c), consensus (12c)


Altimmune Earnings Call Transcript: Q2 2026

Aug 12, 2026, 8:30 AM EDT - 6 days ago

Altimmune Earnings Call Transcript: Q2 2026


Altimmune Earnings release: Q2 2026

Aug 12, 2026, 8:30 AM EDT - 6 days ago

Altimmune Earnings release: Q2 2026


Altimmune Quarterly report: Q2 2026

Aug 12, 2026, 8:30 AM EDT - 6 days ago

Altimmune Quarterly report: Q2 2026


Altimmune Slides: Corporate presentation

Aug 12, 2026, 8:00 AM EDT - 7 days ago

Altimmune Slides: Corporate presentation


Altimmune initiates PERFORMA trial

2026-08-03T12:16:41.000Z - 16 days ago

Altimmune initiates PERFORMA trial


H.C. Wainwright sees ‘clear Phase 2 win’ for Altimmune

2026-07-28T15:20:26.000Z - 21 days ago

H.C. Wainwright sees ‘clear Phase 2 win’ for Altimmune


Altimmune Transcript: Study result

Jul 28, 2026, 8:00 AM EDT - 22 days ago

Altimmune Transcript: Study result


Altimmune Press release: Study result

Jul 28, 2026, 8:00 AM EDT - 22 days ago

Altimmune Press release: Study result


Altimmune Slides: Study result

Jul 28, 2026, 8:00 AM EDT - 22 days ago

Altimmune Slides: Study result


Altimmune announces RECLAIM trial met primary endpoint

2026-07-28T11:26:01.000Z - 22 days ago

Altimmune announces RECLAIM trial met primary endpoint


Altimmune initiated with an Outperform at Leerink

2026-06-22T10:46:24.000Z - 2 months ago

Altimmune initiated with an Outperform at Leerink


Altimmune initiated with an Outperform at Leerink

2026-06-22T10:31:03.000Z - 2 months ago

Altimmune initiated with an Outperform at Leerink


Altimmune to Participate in Upcoming Investor Conferences

May 27, 2026, 8:30 AM EDT - 2 months ago

Altimmune to Participate in Upcoming Investor Conferences


Altimmune Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 3 months ago

Altimmune Slides: Corporate presentation


Altimmune price target lowered to $11 from $14 at Citizens

2026-05-14T09:47:49.000Z - 3 months ago

Altimmune price target lowered to $11 from $14 at Citizens


Altimmune Earnings Call Transcript: Q1 2026

May 13, 2026, 8:30 AM EDT - 3 months ago

Altimmune Earnings Call Transcript: Q1 2026


Altimmune Earnings release: Q1 2026

May 13, 2026, 8:30 AM EDT - 3 months ago

Altimmune Earnings release: Q1 2026


Altimmune Quarterly report: Q1 2026

May 13, 2026, 8:30 AM EDT - 3 months ago

Altimmune Quarterly report: Q1 2026


Altimmune reports Q1 EPS (18c), consensus (25c)

2026-05-13T11:59:47.000Z - 3 months ago

Altimmune reports Q1 EPS (18c), consensus (25c)


Altimmune management to meet with Piper Sandler

2026-04-27T19:56:05.000Z - 4 months ago

Altimmune management to meet with Piper Sandler


Altimmune upgraded to Neutral from Sell at Goldman Sachs

2026-04-24T09:16:13.000Z - 4 months ago

Altimmune upgraded to Neutral from Sell at Goldman Sachs


Altimmune 64.25M share Spot Secondary priced at $3.00

2026-04-23T11:06:36.000Z - 4 months ago

Altimmune 64.25M share Spot Secondary priced at $3.00


Altimmune announces common stock offering, no amount given

2026-04-22T20:28:30.000Z - 4 months ago

Altimmune announces common stock offering, no amount given


Altimmune Transcript: AGM 2026

Apr 16, 2026, 8:30 AM EDT - 4 months ago

Altimmune Transcript: AGM 2026


Altimmune initiated with a Buy at Truist

2026-03-18T20:00:19.000Z - 5 months ago

Altimmune initiated with a Buy at Truist


Altimmune Proxy statement: Proxy Filing

Mar 17, 2026, 8:00 AM EDT - 5 months ago

Altimmune Proxy statement: Proxy Filing


Altimmune Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 9:20 AM EDT - 5 months ago

Altimmune Transcript: Leerink Global Healthcare Conference 2026


Altimmune Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 2:15 PM EDT - 5 months ago

Altimmune Transcript: The Citizens Life Sciences Conference 2026


Altimmune Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Altimmune Slides: Corporate presentation


Altimmune Proxy statement: Proxy Filing

Mar 6, 2026, 7:00 AM EST - 5 months ago

Altimmune Proxy statement: Proxy Filing


Altimmune Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 5 months ago

Altimmune Earnings Call Transcript: Q4 2025


Altimmune Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 5 months ago

Altimmune Annual report: Q4 2025


Altimmune Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 5 months ago

Altimmune Earnings release: Q4 2025


Altimmune Transcript: Study Result

Dec 19, 2025, 8:00 AM EST - 8 months ago

Altimmune Transcript: Study Result


Altimmune Press release: Study Result

Dec 19, 2025, 8:00 AM EST - 8 months ago

Altimmune Press release: Study Result


Altimmune Slides: Study Result

Dec 19, 2025, 8:00 AM EST - 8 months ago

Altimmune Slides: Study Result


Altimmune Announces CEO Transition and Succession Plan

Dec 1, 2025, 7:30 AM EST - 9 months ago

Altimmune Announces CEO Transition and Succession Plan


Altimmune Registration statement: Registration Filing

Nov 13, 2025, 7:00 AM EST - 9 months ago

Altimmune Registration statement: Registration Filing


Altimmune Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:00 AM EST - 9 months ago

Altimmune Transcript: Stifel 2025 Healthcare Conference


Altimmune Slides: Corporate Presentation

Nov 6, 2025, 4:00 PM EST - 10 months ago

Altimmune Slides: Corporate Presentation


Altimmune Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Altimmune Earnings Call Transcript: Q3 2025


Altimmune Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Altimmune Quarterly report: Q3 2025


Altimmune Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Altimmune Earnings release: Q3 2025


Altimmune Registration statement: Registration Filing

Nov 6, 2025, 7:00 AM EST - 10 months ago

Altimmune Registration statement: Registration Filing


Altimmune to Participate in Two Upcoming Investor Conferences

Nov 5, 2025, 7:30 AM EST - 10 months ago

Altimmune to Participate in Two Upcoming Investor Conferences


Altimmune Transcript: Stifel Virtual Cardiometabolic Forum

Sep 30, 2025, 10:30 AM EDT - 11 months ago

Altimmune Transcript: Stifel Virtual Cardiometabolic Forum


Altimmune Transcript: AGM 2025

Sep 25, 2025, 8:30 AM EDT - 11 months ago

Altimmune Transcript: AGM 2025


lottomillions
lottomillions Aug. 19 at 12:17 PM
$ALT The XBI might do it today, ALT and Durso still asleep.
0 · Reply
Turribull
Turribull Aug. 19 at 12:13 PM
$ALT Reverse inverse oppo Cramer.
0 · Reply
TradeSun
TradeSun Aug. 19 at 12:06 PM
$ALT Good morning ☀️ RECLAIM’s positive AUD data were released on July 28. Jerry Durso bought 15,000 shares just 16 days later, likely too soon for newly sparked Big Pharma interest to have developed into advanced, material negotiations. His purchase therefore doesn’t contradict a potential partnership scenario. It suggests that, as of August 13, any possible discussions were probably still too preliminary or non-material to prevent him from buying. The timeline would make sense: -> Positive AUD data attract interest -> Initial contacts and NDAs follow -> Due diligence takes place over the coming months -> The FDA EOP2 meeting provides regulatory clarity -> Concrete offers could emerge thereafter This fits the thesis that RECLAIM may have activated one or more interested parties, just not that a deal was already close to signing when Durso bought.
1 · Reply
ItIsGoTime
ItIsGoTime Aug. 19 at 12:06 PM
$ALT institution held jumps to over 75%
0 · Reply
GreenEnergy7B
GreenEnergy7B Aug. 19 at 11:54 AM
$ALT Flying $MRNA
0 · Reply
ghettobird
ghettobird Aug. 19 at 11:40 AM
1 · Reply
ViperV22
ViperV22 Aug. 19 at 11:35 AM
0 · Reply
szrdz
szrdz Aug. 19 at 11:05 AM
$ALT me looking at moderna
2 · Reply
Jackstradamus
Jackstradamus Aug. 19 at 10:17 AM
$ALT https://www.cnbc.com/video/2026/08/18/lightning-round-avnet-is-a-really-good-stock-says-jim-cramer.html
1 · Reply
Babybock
Babybock Aug. 19 at 10:14 AM
$ALT very
0 · Reply
Damnthisappilosthistory
Damnthisappilosthistory Aug. 19 at 5:29 AM
$ALT yes they are crooks. Durso bought mainly just to instill confidence before major offerings earlier this year, then immediately stopped buying. Wish Pemvi had better mgmt.
0 · Reply
ERAU15
ERAU15 Aug. 19 at 4:59 AM
$ALT I missed it today but my prediction for tomorrow 😂
0 · Reply
BuddyBoy6975
BuddyBoy6975 Aug. 19 at 2:55 AM
$ALT We don’t NEED one 🤣😡😡. Seriously..? Rookie…?
0 · Reply
Chucho64
Chucho64 Aug. 19 at 2:46 AM
$ALT The fact that the percentage of shares held by retail investors is very small is excellent news for those of us who remain; if positive news regarding a partnership or acquisition breaks, there will be no institutional selling, resulting in a severe scarcity of shares. High buying competition: If the news attracts interest, everyone will vie to buy up the remaining 2%. Scarcity effect: A smaller free float means faster, more aggressive price surges in response to large buy orders.💥💥💥💥💰💰💰💰💰💰💰💰💥
1 · Reply
Chucho64
Chucho64 Aug. 19 at 2:14 AM
$ALT When institutions hold 98% of a stock, the "float" (shares available for trading) is only 2%. In the wake of very positive news, this supply shortage causes the price to surge sharply and rapidly. The scarcity effect: Large institutional funds do not sell simply because the price rises slightly; they wait for higher prices, further drying up daily supply. Bullish gap: At market open, the price may jump directly to a much higher level (a gap) because no one is willing to sell at a low price.💥💥💥💥💥
2 · Reply
Chucho64
Chucho64 Aug. 19 at 1:58 AM
$ALT So, only the ST retailers were left.🧐🧐
2 · Reply
Joe___
Joe___ Aug. 19 at 1:53 AM
$ALT For reference thanks to @Kawasaki1
0 · Reply
PemvidutideTrader7B
PemvidutideTrader7B Aug. 19 at 1:39 AM
2 · Reply
Kawasaki1
Kawasaki1 Aug. 19 at 1:03 AM
$ALT Jim Cramer was asked about Altimmune tonight on Mad Money / @CNBC and he said... "I'm IN"!
6 · Reply
Corpkcots
Corpkcots Aug. 19 at 1:03 AM
$ALT The latest Institutional & Insider Ownership numbers from Fintel are screaming buy! They have Institutional Ownership now at 88.6% and Insider Ownership at 10.9%, for a total of 99.5% of the available shares. Go ALT
2 · Reply
Putz20
Putz20 Aug. 19 at 12:50 AM
$ALT when’s the next conference.
1 · Reply
BuddyBoy6975
BuddyBoy6975 Aug. 19 at 12:39 AM
$ALT I’m starting to feel like the closing posting crew here since I work nights and sleep thru 3-4pm
1 · Reply